These phenotypes are contributing to the severity of BMA-induced tumor burden, by driving osteoclastogenesis and thereby osteolytic lesion formation via IL-6 or indirectly via CXCL1 and osteopontin (OPN) (11). The gene discussed is SPP1; the disease is neoplasm.